Amryt announces positive long-term safety and efficacy data for mycapssa® (oral octreotide) from the 2nd year of optimal open label extension study in acromegaly patients

Amryt announces positive long-term safety and efficacy data for mycapssa® (oral octreotide) from the 2 nd year of optimal open label extension study in acromegaly patients
AMYT Ratings Summary
AMYT Quant Ranking